Xpira Pharmaceuticals, a Canada-based developer of next-generation psychedelic medicines for the treatment of eating disorders, announced on Tuesday that it has received approval from the United States Food and Drug Administration (FDA) for its first Investigational New Drug (IND) application to initiate a Phase 2a clinical trial that is intended to assess the efficacy of psilocybin-assisted therapeutic protocols in patients with Anorexia Nervosa (AN).

With this trial, Xpira aims to contribute to the successful outcome of treatment for patients with AN, including enhancing patients' quality of life by furthering the development of its innovative psilocybin-assisted treatment.